NVX-CoV2515 / Novavax 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NVX-CoV2515 / Novavax
NCT05372588: Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines

Completed
3
1340
RoW
NVX-CoV2515, Omicron BA.1 SARS-CoV-2 rS /Matrix-M Adjuvant, NVX-Cov2373, SARS-CoV-2 rS/Matrix-M Adjuvant, NVX-CoV2373 + NVX-CoV2515, Prototype/BA.1 Bivalent Vaccine, NVX-CoV2540, Omicron BA.5 SARS-CoV-2 rS /Matrix-M Adjuvant, NVX-CoV2373 + NVX-CoV2540, Prototype/BA.5 Bivalent Vaccine
Novavax
COVID-19, SARS CoV 2 Infection
07/22
04/24

Download Options